Is Function Health's $450 million a funding round?

Not in the conventional sense. General Catalyst's Customer Value Fund provides non-dilutive, revenue-linked capital that finances a company's sales and marketing spending, and is repaid from the revenue that spending generates rather than taking an equity stake. It is growth financing, structured differently from the $298 million Series B that Function closed in November 2025.

How is this different from Neko Health's raise?

Neko Health closed a $700 million Series C on July 15, 2026, led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. That is an equity round: investors bought ownership. A revenue-share financing and an equity round are different instruments and answer different questions about a business, which is why adding them into a single sector total is misleading.

A fund bet $450 million that prevention pays back

Q: What is General Catalyst's Customer Value Fund?

It is a financing vehicle that funds a company's customer-acquisition spending and receives a capped portion of the value generated by the customers that spending acquires, and is paid only when the company is paid. General Catalyst describes it as a way to finance growth without additional equity dilution. The size of the capped revenue share on the Function deal was not disclosed.

Almost every account of the deal reported the same number and missed what the number bought. On July 30, 2026, Function closed $450 million in growth financing from General Catalyst’s Customer Value Fund, eight months after a $298 million Series B. The headline treated it as the next, larger raise. It is not a raise in the ordinary sense at all, and the difference is the whole story.

A fund that gets paid when the customer pays. What did it actually buy?

Start with the instrument, because the instrument is the claim. General Catalyst’s Customer Value Fund does not purchase equity. It finances a company’s sales and marketing spending and, in the fund’s own description, receives a capped portion of the value generated by the customers that spending acquires, and is paid only when the company is paid. General Catalyst frames it as a way to finance growth without additional equity dilution. The Customer Value Fund finances a company’s sales and marketing spending rather than purchasing equity, so the financing is not a funding round in the conventional sense.

That structure carries a buried premise. An investor who buys equity is betting that the company is worth more later. A financier who funds your customer acquisition and is repaid only out of what those customers pay is betting something narrower and harder: that each dollar spent acquiring a member returns a knowable amount of revenue on a knowable schedule. You cannot underwrite a business that way unless the payback is provable. For a company selling preventive diagnostics, that is a wager that prevention itself pays back, and pays back predictably enough to lend against.

What the record shows:

Function closed $450 million in growth financing from General Catalyst’s Customer Value Fund on July 30, 2026, per the company’s announcement, eight months after a $298 million Series B closed in November 2025.
The financing is non-dilutive and revenue-linked, structured as a claim on future customer revenue rather than an equity stake, per MobiHealthNews.
The size of the capped revenue share was not disclosed.

The most common failure: the headline number. Reporting the size of a raise while ignoring what was actually sold. A revenue-share financing and a priced equity round can carry the same dollar figure and mean opposite things about how much of the company changed hands, and the figure alone hides which one happened.

A dollar a day against a $4.9 trillion bill. Provable to whom?

The case Function makes for itself is an economic one. Its bundled membership runs about a dollar a day, and the argument is that early detection is cheaper than treating the disease it finds later, against a United States health bill where the overwhelming share of spending goes to conditions that were detectable years earlier. Whether early detection improves outcomes at the population level is contested in the clinical literature, and a record does not adjudicate it. That is not what the financing settles.

What the financing tests is narrower and more concrete. Revenue-share capital does not need the population-health question resolved. It needs the unit economics to hold: acquire a member for a knowable cost, keep the member long enough, collect a knowable amount. General Catalyst’s willingness to be repaid out of that stream, rather than out of a future sale of the company, is a statement that Function’s own numbers on member acquisition and retention are firm enough to lend against. That is a real claim, and it is a smaller one than the marketing makes. It is worth keeping the two apart.

The most common failure: the borrowed proof. Treating a financier’s confidence in a company’s unit economics as if it were evidence for the company’s clinical thesis. The first is a bet on a spreadsheet. The second is a question for a trial.

Four raises in one quarter. One number?

The summer of 2026 produced a run of large numbers in preventive health, and the temptation is to add them up. Function’s $450 million sits in the same window as Neko Health’s $700 million Series C, closed July 15, 2026, led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Set beside other consumer-health raises from the same months, the sector looks like it took on well over a billion dollars. The sum is meaningless, because the instruments are not the same instrument.

Neko sold equity. Investors bought ownership and are betting on the company’s future value. Function did not sell equity in this deal; it sold a claim on the revenue that its marketing spend produces. One is a bet on the enterprise, the other a bet on a cohort of customers. Averaging them into a sector total erases the one distinction that tells you what kind of confidence the money represents. This is why the record keeps the type, not only the size.

What the record shows:

The Atlas of the Healthspan Economy records financing type alongside amount, because a revenue-share financing and an equity round are different claims about a business.
Function Health and Neko Health both sit in the Atlas under the Healthtech and Diagnostics pillar, recorded with the financing type on each, so a growth-financing arrangement and a priced equity round remain distinguishable rather than collapsed into one running total.

The most common failure: the sector sum. Adding a revenue-share financing, an equity round and a debt facility into a single number for how much capital a category raised. The total looks authoritative and describes nothing, because it averages away the terms that gave each figure its meaning.

What a record does instead

The useful response to a quarter of big numbers is not to add them. It is to keep the field that tells you what each number is. Amount answers how much. Type answers on what terms, and terms are where a revenue-share financing stops being interchangeable with an equity round. Record both, date both, and the reader can see that a fund agreed to be paid back from Function’s customer revenue, which is a more specific and more falsifiable statement about prevention than a valuation ever is.

None of this settles whether preventive diagnostics earns its keep across a population. It sharpens what has actually been asserted, and by whom, and on what schedule they expect to be right. A record does not need the clinical question answered to do that. It needs to stop reporting the price and start reporting the instrument.

The Atlas of the Healthspan Economy is a neutral record of organizations working on healthspan. It records financing type alongside amount. It does not recommend. See Function Health and Neko Health in the Healthtech & Diagnostics pillar, and read the methodology.

A note on what this piece does not claim. Deal terms are as reported by the sources and dates cited. The size of the capped revenue share on the Function financing was not disclosed, and this piece does not estimate it. Nothing here values Function or characterizes the merits of its clinical thesis, which remains contested in the literature.